Literature DB >> 32103409

Toxicity of ayahuasca after 28 days daily exposure and effects on monoamines and brain-derived neurotrophic factor (BDNF) in brain of Wistar rats.

Camila Schoueri Colaço1, Stefany Sousa Alves1, Luciana Marangni Nolli1, Willie Oliveira Pinheiro2, Danilo Gustavo Rodrigues de Oliveira3, Beatriz Werneck Lopes Santos1, Aline Pic-Taylor2, Márcia Renata Mortari3, Eloisa Dutra Caldas4.   

Abstract

Ayahuasca is a hallucinogenic beverage that affects the serotonergic system and have therapeutic potential for many diseases and disorders, including depression and drug addiction. The objectives of this study were to evaluate the potential toxic effects of ayahuasca on rats after chronic exposure, and the levels of monoamines, their metabolites and the brain-derived neurotrophic factor (BDNF) in the brain. Female and male rats were treated orally for 28 days with H2O (control), fluoxetine (FLX), a selective serotonin reuptake inhibitor antidepressant, or ayahuasca (Aya) at doses of 0.5X, 1X and 2X the ritualistic dose (7 to 10 animals/group). Clinical, hematological and macroscopic results showed that ayahuasca was safe to the rats. Behavior tests conducted one hour after the last treatment showed that male rats from the Aya1 group explored the open field central area less than the control group, and the number of entries in the central area compared to total locomotion was also significantly lower in this group and in the FLX group. The hippocampus was removed for BDNF analysis and the remaining brain was used for monoamine analysis by HPLC-FL. Serotonin levels were significantly higher than control only in the Aya2 female group, while a significant reduction of its metabolite 5-HIAA was observed in the FLX group. Dopamine levels were similar among the experimental groups, but the levels of its metabolite DOPAC increased significantly in the Aya1 and Aya2 groups compared to controls, especially in females, and the DOPAC/dopamine turnover was significantly higher in Aya2 group. The levels of HVA, another dopamine metabolite, did not change with the treatments compared to controls, but HVA/DOPAC ratio was significantly lower in all ayahuasca male groups. Norepinephrine was not detected in any brain sample, and the levels of its metabolite MHPG did not change significantly among the groups. BDNF levels in the hippocampus were significantly higher in the FLX and Aya2 female groups compared to controls when expressed in relation to the total brain weight. The mechanisms involved in the increase in serotonin, dopamine turnover and BDNF levels observed in ayahuasca treated animals should be further investigated in specific brain areas.

Entities:  

Keywords:  Ayahuasca; BDNF; Brain; Depression; Dopamine; Serotonin

Mesh:

Substances:

Year:  2020        PMID: 32103409     DOI: 10.1007/s11011-020-00547-w

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  4 in total

Review 1.  The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials.

Authors:  Giordano Novak Rossi; Jaime E C Hallak; Glen Baker; Serdar M Dursun; Rafael G Dos Santos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-07-13       Impact factor: 5.760

Review 2.  Psychedelic-inspired approaches for treating neurodegenerative disorders.

Authors:  Hannah N Saeger; David E Olson
Journal:  J Neurochem       Date:  2021-12-05       Impact factor: 5.546

3.  Effects of Transient Electrical Acupuncture Stimulation Combined With Rehabilitation Training on Hemorheology, Neurological Function and BDNF in Patients With Cerebral Infarction.

Authors:  Shuangqin Chen; Jianghua Huang; Xuan Tang; Ting Wang; Yahua Zeng
Journal:  Front Surg       Date:  2022-02-15

4.  Components of Banisteriopsis caapi, a Plant Used in the Preparation of the Psychoactive Ayahuasca, Induce Anti-Inflammatory Effects in Microglial Cells.

Authors:  Beatriz Werneck Lopes Santos; Daniel Carneiro Moreira; Tatiana Karla Dos Santos Borges; Eloisa Dutra Caldas
Journal:  Molecules       Date:  2022-04-13       Impact factor: 4.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.